Cost-effectiveness of dapagliflozin plus standard treatment compared to standard therapy for the management of chronic kidney disease in Colombia.
Expert Rev Pharmacoecon Outcomes Res
; : 1-11, 2024 Jul 24.
Article
en En
| MEDLINE
| ID: mdl-39045630
ABSTRACT
BACKGROUND:
The DAPA-CKD study showed that dapagliflozin added to standard treatment reduced the risk of chronic kidney disease progression, and death from renal or cardiovascular causes compared to placebo.OBJECTIVE:
Assess the cost-effectiveness of dapagliflozin and standard treatment versus standard treatment alone for chronic kidney disease within the Colombian health system.METHODS:
We employed a Markov model based on the DAPA-CKD study, tailored to the Colombian scenario. The model forecasted hospitalizations for heart failure, overall and cardiovascular mortality, and chronic kidney disease progression over a 10-year horizon with a 5% discount rate.RESULTS:
Dapagliflozin combined with standard treatment is a cost-effective intervention in treating stage 2-4 CKD. In the base case, the ICER was US $5,366, below 1 GDP (US $6.558) per capita. This was consistent in the sensitivity analyses.CONCLUSION:
Our study showed that dapagliflozin, when combined with standard treatment, is cost-effective against standard treatment alone, aligning with Colombia's willingness-to-pay threshold.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
País/Región como asunto:
America do sul
/
Colombia
Idioma:
En
Revista:
Expert Rev Pharmacoecon Outcomes Res
/
Expert rev. pharmacoecon. outcomes res
/
Expert review of pharmacoeconomics and outcomes research
Asunto de la revista:
FARMACOLOGIA
Año:
2024
Tipo del documento:
Article
País de afiliación:
Colombia
Pais de publicación:
Reino Unido